

# Shigellosis: Causes, Symptoms, Diagnosis, Treatment and Prevention

Deepa Pillai\*

Department of Neuroscience, Osmania University, India

## Introduction

Shigellosis is a bacterial infection caused by *Shigella* species, which leads to acute diarrheal illness. It is a significant public health concern, particularly in developing countries, where sanitation and hygiene may be inadequate. The disease spreads easily through contaminated food, water, or direct person-to-person contact, making it highly infectious even at low doses. Symptoms range from mild diarrhea to severe dysentery, posing a risk of dehydration and complications if left untreated. This article explores the causes, symptoms, diagnosis, treatment, and prevention of shigellosis, providing a comprehensive understanding of this gastrointestinal infection. Shigellosis is a bacterial infection caused by *Shigella* species, primarily affecting the gastrointestinal tract. It is a major public health concern worldwide, particularly in regions with inadequate sanitation and poor hygiene. The disease is highly contagious and spreads easily through contaminated food, water, and direct person-to-person contact. Even a small number of bacteria can cause infection, making it one of the most infectious diarrheal diseases. Shigellosis manifests as a range of symptoms, from mild diarrhea to severe dysentery, characterized by bloody stools, abdominal pain, and fever. While most cases are self-limiting, severe infections can lead to complications such as dehydration, hemolytic uremic syndrome (HUS), and malnutrition, especially in children and immunocompromised individuals. The disease is responsible for significant morbidity and mortality, particularly in developing countries where access to clean water and medical care is limited. The increasing prevalence of antibiotic-resistant *Shigella* strains poses a serious challenge to treatment. Over the past few decades, multidrug-resistant (MDR) strains have emerged, limiting the effectiveness of commonly used antibiotics such as fluoroquinolones and sulphonamides [1,2]. This has led to an urgent need for improved treatment strategies, better sanitation, and vaccine development to control the spread of the disease. Preventive measures such as proper handwashing, safe food handling, improved sanitation, and access to clean drinking water remain critical in reducing the incidence of shigellosis. Research efforts are currently focused on developing an effective *Shigella* vaccine to provide long-term protection, especially in endemic areas. This article provides a comprehensive overview of the causes, symptoms, diagnosis, treatment, and prevention of shigellosis, highlighting key challenges and public health strategies to mitigate its impact [3,4].

## Discussion

Shigellosis is a major public health concern due to its high transmissibility, low infectious dose, and increasing antibiotic resistance. The disease is particularly problematic in developing countries, where inadequate sanitation, poor water quality, and lack of access to healthcare contribute to frequent outbreaks. However, industrialized nations are not exempt, as foodborne transmission and person-to-person spread remain significant risks [5].

One of the most critical issues in managing shigellosis is antibiotic resistance. In recent years, multi-drug resistant (MDR) *Shigella* strains have emerged, making treatment more challenging. The overuse and

misuse of antibiotics have accelerated resistance, particularly against fluoroquinolones and sulfonamides. As a result, there is a growing need for alternative treatments, enhanced surveillance, and judicious antibiotic use to prevent further resistance development [6].

Shigellosis disproportionately affects young children, the elderly, and immunocompromised individuals, leading to increased morbidity and mortality in these groups. Outbreaks in daycare centers, schools, and refugee camps highlight the importance of strict hygiene measures to control its spread. In these settings, proper handwashing, improved sanitation, and access to clean drinking water play a crucial role in reducing infection rates [7].

Efforts to develop a *Shigella* vaccine are ongoing, with several candidates in clinical trials. A vaccine would provide a significant breakthrough in reducing the global burden of shigellosis, particularly in endemic regions where repeated infections contribute to childhood malnutrition and growth impairment [8].

In conclusion, while shigellosis is largely preventable, challenges such as antibiotic resistance, inadequate sanitation, and lack of vaccines continue to hinder control efforts. Strengthening public health infrastructure, promoting hygiene education, and developing new treatments are essential to combatting this highly contagious disease [9].

## Causes and Transmission

Shigellosis is caused by bacteria from the *Shigella* genus, which includes four major species:

*Shigella dysenteriae* (most severe infections and associated with Shiga toxin production)

*Shigella flexneri* (common in developing nations)

*Shigella boydii* (less common)

*Shigella sonnei* (most common in industrialized nations)

The infection spreads via the fecal-oral route, with transmission occurring through:

Contaminated food and water: Ingesting food or water contaminated with fecal matter from an infected person.

**\*Corresponding author:** Deepa Pillai, Department of Neuroscience, Osmania University, India, Email: deepa@pillai.com

**Received:** 03-Mar-2025, Manuscript No: JNID-25-162531, **Editor Assigned:** 07-Mar-2025, Pre QC No: JNID-25-162531 (PQ), **Reviewed:** 18-Mar-2025, QC No: JNID-25-162531, **Revised:** 22-Mar-2025, Manuscript No: JNID-25-162531 (R), **Published:** 29-Mar-2025, DOI: 10.4172/2314-7326.1000560

**Citation:** Deepa P (2025) Shigellosis: Causes, Symptoms, Diagnosis, Treatment and Prevention. J Neuroinfect Dis 16: 560.

**Copyright:** © 2025 Deepa P. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Direct person-to-person contact: Especially in crowded environments such as daycares, schools, and nursing homes.

Flies and contaminated surfaces: Flies can carry bacteria from fecal matter to food, and infected surfaces can contribute to indirect transmission [10].

### Symptoms of Shigellosis

The incubation period of shigellosis is typically 1-3 days, after which symptoms manifest. The severity of the illness depends on the strain of *Shigella* and the host's immune status. Common symptoms include:

- Diarrhea (often bloody or mucous-filled)
- Abdominal cramps and pain
- Fever and chills
- Tenesmus (a constant feeling of needing to pass stool even when the bowel is empty)
- Nausea and vomiting
- Dehydration (due to fluid loss)

Severe cases, particularly those caused by *S. dysenteriae*, can lead to hemolytic uremic syndrome (HUS), a life-threatening condition that causes kidney failure.

### Treatment of Shigellosis

Most cases of shigellosis resolve on their own within 5-7 days, but severe infections require medical intervention. Treatment options include:

#### Rehydration Therapy

Oral rehydration salts (ORS): To prevent dehydration caused by diarrhea.

Intravenous fluids (IV): Required for severe dehydration cases.

#### Antibiotic Therapy

Antibiotics are recommended for severe or prolonged infections, particularly in vulnerable populations such as children, elderly individuals, and immunocompromised patients. Commonly used antibiotics include:

- Azithromycin
- Ciprofloxacin
- Ceftriaxone

Trimethoprim-sulfamethoxazole (TMP-SMX) (only in non-resistant strains)

However, antibiotic resistance is a growing concern, particularly with multi-drug resistant (MDR) *Shigella* strains. This has made treatment more challenging, necessitating regular surveillance of resistance patterns.

### Symptomatic Management

Antipyretics (e.g., acetaminophen): To reduce fever.

Avoid anti-motility agents (e.g., loperamide): These can worsen the condition by preventing bacterial clearance from the gut.

### Conclusion

Shigellosis is a highly contagious bacterial infection caused by *Shigella* species, primarily affecting the intestinal tract. It spreads through the fecal-oral route, often due to poor sanitation, contaminated food and water, or person-to-person contact. The disease predominantly affects young children, travelers, and individuals in crowded living conditions. In conclusion, shigellosis remains a global health concern, particularly in developing regions with inadequate sanitation and hygiene. While most cases are mild and self-resolving, severe infections can lead to complications and mortality, especially in vulnerable populations. Strengthening public health infrastructure, promoting hygiene practices, and developing effective vaccines are essential steps in controlling shigellosis and reducing its impact worldwide.

### References

1. Rose SW, Penry JK, Markush RE (1973) Prevalence of epilepsy in children. *Epilepsia* 14:133-152.
2. Quinones NM, Lira MD (2004) Epidemiological profile of epilepsy in a hospital population Lima, Peru. *Rev Neurol*. 38:712-715.
3. Sharma K (2005) Genetic epidemiology of epilepsy a twin study. *Neurol India* 53:93- 98.
4. Hauser WA (2000) Epidemiology of epilepsy. *World Neurology* 15:6- 8.
5. Danesi MA, Odusote KA, Roberts OO (1981) Social problems of adolescent and adult epileptics in a developing country, as seen in Lagos, Nigeria. *Epilepsia* 22:689-695.
6. Davis A, Meintjes G, Wilkinson RJ (2018) Treatment of Tuberculosis Meningitis and Its Complications in Adults. *Curr Treat Opti Neurol* 20: 5.
7. Mezocho A, Thakur K, Vinnard C (2017) Tuberculosis Meningitis in Children and Adults: New Insights for an Ancient Foe. *Curr Neurol Neurosis Rep* 17:85.
8. Heemskerk AD, Bang ND, Mai NTH, Chau TTH, Phu NH, et al. (2016) Intensified Antituberculosis Therapy in Adults with Tuberculous Meningitis. *N Engl J Med* 374:124-134.
9. Van Laarhoven A, Dian S, Ruesen C, Hayati E, Damen MSMA, et al. (2017) Clinical parameters, routine inflammatory markers, and LTA4H genotype as predictors of mortality among 608 patients with tuberculous meningitis in Indonesia. *J Infect Dis* 215:1029-1039.
10. Gunarsa RG, Simadibrata M, Syam AF, Timan IS, Setiati S, et al. (2015) Total Lymphocyte Count as a Nutritional Parameter in Hospitalized Patients. *Indones J Gastro Hepatol Dig Endosc* 12:89-94.